NCT03466827 - Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2017

Primary Completion Date

July 1, 2020

Study Completion Date

July 1, 2020

Conditions

ThymomaAdvanced Thymic Epithelial Tumour

Interventions

DRUG

Selinexor

Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.

Trial Locations (4)

2100

RECRUITING

Rigshospitalet, Copenhagen

Unknown

NOT_YET_RECRUITING

Hospices Civils de Lyon, Lyon

NOT_YET_RECRUITING

Intitut Curie, Paris

NOT_YET_RECRUITING

Intitut Gustave Roussy, Paris